Objective. Тс determine allelic variants frequencies caused by Apo E polymorphism in patients with metabolic syndrome and cognitive dysfunction (CD). Design and methods. 54 participants had undergone anthropometric measurements, blood examination (glucose, cholesterol and triglycerides), molecular genetic analysis (polymerase chain reaction, restriction fragments length polymorphism) and neuropsychological tests. Results. Allelic variant s4 of Apo E is an unfavourable factor contributing to the development of CD, depression, anxiety disorders. Allelic variant s2 of Apo E is protective factor in relation to the development of depression.
Информация об авторахДьяченко Николай Александрович -аспирант кафедры госпитальной терапии с курсом аллергологии и иммунологии им. акад. М.В.Черноруцкого Федерального государственного бюджетного образовательного учреждения высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; тел.:
The review is devoted to the key component of plasma hemostasis — blood coagulation factor V. The structure of this protein and the F5 gene encoding it, its role in the hemostasis system, interaction with other coagulation factors and the natural anticulant protein C are considered. Particular attention is paid to the genetic defects of F5, which determine both hemorrhagic complications and a hereditary tendency to increased thrombus formation. Among the latter, the Leiden mutation of coagulation factor V (FV Leiden), which is hereditary thrombophilia and is considered as a risk factor for the development of venous thromboembolic complications, is described in detail.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.